THE stress and anxiety are a common experience that can have a significant impact on our mental and emotional well-being. Understanding the mechanisms behind the reaction of our body to stress is crucial to develop effective treatments against psychiatric disorders. In a recent study, researchers have discovered that the Endocannabinoid system, a complex network of receptors and molecules present in our body plays a key role in our response to stress. These discoveries open up new possibilities to treat psychiatric disorders using cannabinoids.
Endocannabinoid system and stress
The endocannabinoid system is a system of regulation of our body which is involved in various physiological processes, including mood regulation, pain perception and stress response. It consists of endocannabinoids, naturally produced by our body, and cannabinoid receptors present throughout the brain and the body.
Understand the endocannabinoide system in video:
A less known fact about CBD is that it can potentially help eliminate the feeling of paranoia that some people feel when they consume THC.
We do not say that the CBD will make you feel less poisoned, but it can help balance intoxication.
When some people take too much THC, they can suddenly feel uncontrollable or paranoid. This is why more and more people turn to the CBD to help relieve this effect.
In the study, the researchers focused on a crucial brain emotional center called thetonsil. They discovered that the amygdal releases endocannabinoids in answer At stress, which then activate the same receptors in the brain as THC, the psychoactive compound derived from cannabis plants. This activation helps to alleviate the response to stress issued by the hippocampus, another important brain center involved in memory and emotions.
However, specific brain activity models and neural circuits regulated by these endocannabinoids are not well understood. Additional research is necessary to fully understand the mechanisms at stake.
The natural response to stress
These results confirm the hypothesis that endocannabinoids are the natural response of the stress. Exposure to stress Increase the risk of developing or to exacerbate psychiatric disorders, ranging from generalized anxiety to depression major and disorder post-traumatic stress (SSPT).
To conduct the study, scientists of Northwestern Medicine used a new protein sensor capable of detecting in real time the presence of these endocannabinoids in specific brain synapses.
The sensor has shown that high -frequency specific activity models in the amygdal can generate these molecules. The sensor also revealed that these molecules were released following different types of stress in mice.
When scientists have deleted the target of these endocannabinoids, the type 1 cannabinoid receiver (CB1), this trained a reduction of the Ability to deal with stress and a motivation deficit among mice.
More specifically, when the target receptor of these endocannabinoids was removed in the hippocampal-amygdal synapses, the mice presented more passive and immobile reactions to stress and showed less preference for the consumption of sweet water after exposure to stress.
This observation could be linked to the anhedonia, the decrease in the ability to experience pleasure, often felt by patients with stress -related disorders such as depression and SSPT.
Implications for treatment
THE Dr Sachi Patel, corresponding author of the study and holder of the chair of psychiatry and behavioral sciences at Feinberg School of Medicine from Northwestern University, underlined the importance of understanding how the brain adapts to stress at molecular, cellular levels and circuits. This understanding could provide crucial information on how stress results in mood disorders and reveal new therapeutic targets for stress -related disorders.
According to Dr. Patel, the study could indicate that deficiencies in the endocannabinoid signaling system in the brain could lead to greater susceptibility to the development of stress -related psychiatric disorders, including depression and SSPT. However, additional research is necessary to determine this in humans.
The endocannabinoid system has been identified as a key candidate for the development of drugs targeting stress -related psychiatric disorders. Dr. Patel suggests that the next logical step of this research is to determine whether increasing levels of endocannabinoids can be used as potential therapeutic approach for stress -related disorders.
He also notes that the current clinical trials in this area could provide answers to this question in the near future.
Research was funded by subsidies from the National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism and Integrative Neuroscience on Alcoholism, which are all which are all Institutions of the National Institutes of Health.
Conclusion
THE Role of the endocannabinoid system In our response to stress is a fascinating field of research. Understanding how this complex system regulates the reaction of our brain to stress can provide valuable information on the development of effective treatments against psychiatric disorders. THE results a study recent, showing the release of endocannabinoids in response to stress and their impact on behavior related to stress in mice, put in evidence THE potential to target the endocannabinoid system for interventions therapeutics.
Although the study was conducted on mice, additional research is necessary to determine the applicability of these results to humans. Current clinical trials and future research will bring more light to the potential use of endocannabinoids as therapeutic approach for stress -related disorders.
Faq
Q: What is the endocannabinoid system?
The endocannabinoid system is a complex network of receptors and molecules in our body which is involved in various physiological processes, including mood regulation, pain perception and stress response.
Q: How does the endocannabinoid system react to stress?
In response to stress, the endocannabinoid system releases endocannabinoids, which activate cannabinoid receptors in the brain. This activation contributes to alleviating the response to stress and regulating emotional centers of the brain.
Q: What are the endocannabinoids?
The endocannabinoids are molecules produced naturally in our body and whose structure is similar to that of the cannabinoids present in cannabis plants. They bind to cannabinoid receptors and play a role in regulating various physiological processes.
Q: What is the tonsil?
Amygdale is an emotional center of the brain that plays a crucial role in the treatment of emotions, including fear and anxiety. It is involved in the response to stress and interacts with other regions of the brain to regulate emotional and behavioral responses.
Q: How do the discoveries of this study contribute to the field of psychiatry?
The results of this study give an overview of the role of the endocannabinoid system in regulating brain response to stress. Understanding these mechanisms can help develop new therapeutic approaches for stress -related psychiatric disorders.
Q: Can the results of this study be applied to humans?
Although the study was conducted on mice, it is a basis for more in -depth research in humans. Current clinical trials and future research will determine the applicability of these results to stress -related human disorders.
Q: What are the stress -related psychiatric disorders?
Psychiatric stress disorders include generalized anxiety disorder, major depression and post-traumatic stress disorder (SSPT). These disorders can have a significant impact on the mental and emotional well-being of an individual.
Q: What are the potential therapeutic implications of this study?
The study suggests that targeting the endocannabinoid system could provide potential therapeutic advantages for stress -related psychiatric disorders. Additional research is necessary to explore the efficiency and safety of such interventions in humans.
Q: How can understanding the endocannabinoid system help develop treatments for psychiatric disorders?
Understanding the role of the endocannabinoid system in the regulation of stress responses and emotional centers of the brain can provide valuable information on the underlying mechanisms of psychiatric disorders. This knowledge can guide the development of targeted therapies for these disorders.
Q: Are there any current clinical trials related to this research?
Yes, clinical trials are underway on the use of cannabinoids and therapies based on endocannabinoids for various psychiatric disorders. These trials aim to assess the efficiency and security of these interventions in human populations.
